Plain-English translation of NCT03217396 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Researchers are looking for hidden signals in your blood and spinal fluid that could tell them how multiple sclerosis will develop over time. These signals — called biomarkers — are like early warning signs that might help doctors predict disease progression and someday personalize treatment. The study will compare samples from people with MS, people with other neurological diseases, and healthy volunteers to find what's different.
Multiple sclerosis damages nerve connections in ways doctors don't fully understand yet. Finding reliable markers in blood and spinal fluid could help doctors predict who will have a faster disease course and tailor treatment plans earlier, before more damage happens.
You likely qualify if…
You likely don't qualify if…
You will have a lumbar puncture (spinal tap) to collect spinal fluid and a blood draw to collect blood samples. Researchers will then analyze these samples in the laboratory, looking for specific molecules and genetic variations that relate to how your MS progresses. The study involves one visit for sample collection; there is no medication to take or long-term follow-up visits required.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Italy
Sponsor
Neuromed IRCCS
Collaborators
IRCCS Multimedica
Enrollment target
~300 participants
Started
November 2017
Primary completion
September 2026
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in October 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Diego Centonze, MD
IRCCS Neuromed
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.